Citigroup’s Blueprint Medicines BPMC Stock Holding History

Citigroup’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-23,000	Closed	-$2.95M	–	6101
2025 Q2	$2.95M	Hold	23,000	–	–	﹤0.01%	2339
2025 Q1	$2.04M	Buy	+23,000	New	+$2.24M	﹤0.01%	2696
2023 Q4	–	Sell	-25,000	Closed	-$1.26M	–	5708
2023 Q3	$1.26M	Hold	25,000	–	–	﹤0.01%	2325
2023 Q2	$1.58M	Hold	25,000	–	–	﹤0.01%	2436
2023 Q1	$1.12M	Hold	25,000	–	–	﹤0.01%	2448
2022 Q4	$1.1M	Sell	25,000 -13,000	-34%	-$623K	﹤0.01%	2538
2022 Q3	$2.5M	Buy	38,000 +18,000	+90%	+$1.16M	﹤0.01%	1991
2022 Q2	$1.01M	Buy	+20,000	New	+$1.17M	﹤0.01%	2633

Other funds holding BPMC

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Citigroup's BPMC Position: Q3 2025 in Review

Citigroup sold out of Blueprint Medicines (BPMC) in Q3 2025, closing a stake of 154,048 shares — an estimated $19.7M sold.

Citigroup first reported a position in BPMC in Q2 2015 and held it in 41 quarters. The position peaked at $27M in Q1 2025. 5 funds tracked by Wall St. Rank hold BPMC as of Q3 2025.

Citigroup reported no remaining Blueprint Medicines position as of Q3 2025 after selling out during the quarter.
Citigroup sold 154,048 Blueprint Medicines shares in Q3 2025, an estimated $19.7M.
Citigroup first reported a position in Blueprint Medicines in Q2 2015 and held it in 41 quarters.
Citigroup's Blueprint Medicines position peaked at $27M in Q1 2025.
5 funds tracked by Wall St. Rank held Blueprint Medicines as of Q3 2025.

Based on Citigroup's 13F filing for Q3 2025, filed 10 Nov 2025.